{"id":"W4207018194","doi":"10.1093/cid/ciac036","title":"Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"ViiV Healthcare","keywords":"Tenofovir alafenamide; Dolutegravir; Medicine; Discontinuation; Regimen; Internal medicine; Adverse effect; Lamivudine; Population; Tolerability; Viral load; Emtricitabine; Immunology; Human immunodeficiency virus (HIV); Virus; Hepatitis B virus; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001658205,0.0002958421,0.001413516,0.00009687486,0.0002904465,0.00001970627,0.0001760244,0.00007137088,0.00003842174],"category_scores_gemma":[0.007375756,0.0001652755,0.0002677386,0.0004056249,0.0002839678,0.00008433207,0.000191921,0.0003255658,9.863088e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001276547,"about_ca_system_score_gemma":0.0002971964,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005776052,"about_ca_topic_score_gemma":0.000352872,"domain_scores_codex":[0.9965853,0.0007516487,0.00141763,0.0005857518,0.0003355283,0.0003241244],"domain_scores_gemma":[0.9869646,0.011597,0.0007064707,0.0004548613,0.0001552507,0.0001218308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9754558,0.005404665,0.01375304,0.00005549352,0.0003100669,0.00003395057,0.001947951,0.0001054659,0.0004984539,0.00005280287,0.0001996404,0.002182672],"study_design_scores_gemma":[0.9544334,0.00943408,0.03180403,0.001312421,0.0008813654,0.000002048418,0.0005881205,0.0007139973,0.0001525388,0.0001067645,0.0003212643,0.000249976],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935142,0.0004201745,0.0003256105,0.000646454,0.0003258414,0.004284831,0.0003297744,0.00006019065,0.00009296185],"genre_scores_gemma":[0.9985095,0.0001922689,0.0003803851,0.0001284982,0.0000904567,0.0003719147,0.0001914864,0.00002861885,0.0001069154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0210224,"threshold_uncertainty_score":0.8830001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03473619077966352,"score_gpt":0.359169077596887,"score_spread":0.3244328868172235,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}